Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15-year experience.

Topical tacrolimus in adult atopic dermatitis: a consensus based on a 15-year experience. G Ital Dermatol Venereol. 2019 Nov 18;: Authors: Calzavara-Pinton P, Fabbrocini G, Girolomoni G, Matiucci A, Micali G, Musumeci ML, Patruno C, Pellacani G, Rossi MT, Stingeni L, Castello M Abstract Atopic dermatitis (AD) is one of the most common cutaneous inflammatory diseases both in adults and in children. It is a chronic, remitting-relapsing dermatitis, primarily managed by dermatologists, but also by allergists and primary care physicians. Due to coexistence of comorbidities, often a multidisciplinary team is required. Topical calcineurin inhibitors (TCIs - i.e. tacrolimus and pimecrolimus) are a class of steroid- sparing, anti-inflammatory agents that have been shown to be efficacious for the treatment ofAD acute flares and in maintenance therapy. In particular, the application of tacrolimus ointment twice daily reduces AD severity and pruritus. Moreover, maintenance therapy with an intermittent application of tacrolimus to recurrent skin sites (proactive therapy) decreases frequency and severity of relapses. Many studies have also assessed the efficacy of TCIs in disorders other than AD. Although US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) issued a "black box warning" regarding the possible cancerogenic activity of these drugs, there is currently no strong evidence of an increased rate of malignancy in tr...
Source: Giornale Italiano di Dermatologia e Venereologia - Category: Dermatology Tags: G Ital Dermatol Venereol Source Type: research